Statistical testing of shared genetic control for potentially related
  traits by Wallace, Chris
Statistical testing of shared genetic control for potentially related traits
Chris Wallace
(Corresponding author)
Department of Medical Genetics
JDRF/Wellcome Trust Diabetes and Inflammation Laboratory
NIHR Cambridge Biomedical Research Centre
Cambridge Institute for Medical Research
University of Cambridge
Wellcome Trust/MRC Building
Cambridge
CB2 0XY
UK
+44 (0)1223 761093
chris.wallace@cimr.cam.ac.uk
1
ar
X
iv
:1
30
1.
55
10
v2
  [
q-
bio
.G
N]
  3
0 A
pr
 20
13
Abstract
Integration of data from genome-wide single nucleotide polymorphism (SNP) association
studies of different traits should allow researchers to disentangle the genetics of potentially
related traits within individually associated regions. Formal statistical colocalisation testing of
individual regions, which requires selection of a set of SNPs summarizing the association in a
region. We show that the SNP selection method greatly affects type 1 error rates, with published
studies having used methods expected to result in substantially inflated type 1 error rates.
We show that either avoiding variable selection and instead testing the most informative
principal components or integrating over variable selection using Bayesian model averaging
can lead to correct control of type 1 error rates. Application to data from Graves’ disease and
Hashimoto’s thyroiditis reveals a common genetic signature across seven regions shared between
the diseases, and indicates that in five of six regions associated with Graves’ disease and not
Hashimoto’s thyroiditis, this more likely reflects genuine absence of association with the latter
rather than lack of power. Our examination, by simulation, of the performance of colocalisation
tests and associated software will foster more widespread adoption of formal colocalisation test-
ing. Given the increasing availability of large expression and genetic association data sets from
disease-relevant tissue and purified cell populations, coupled with identification of regulatory
sequences by projects such as ENCODE, colocalisation analysis has the potential to reveal both
shared genetic signatures of related traits and causal disease genes and tissues.
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Introduction
In recent years, genome-wide association studies (GWAS) have facilitated a dramatic increase
in the number of genetic variants associated with human disease and other traits such as gene
expression. Understanding the means by which these variants exert their effect will aid the design
of the detailed functional followup studies already underway. Although the causal variants are
not commonly known, multiple traits have been mapped to the same genetic loci, raising the
possibility that the same variants affect multiple traits either directly or with one trait mediating
the other. For example, genetic susceptibility to type 2 diabetes across 12 loci appears mediated
by the genetic influence on body mass index [Li et al., 2011]. Within individual loci, researchers
are examining the genetic association signals from pairs of traits in parallel, with similar results
interpreted as evidence that the two traits may colocalise, or share a common causal variant. These
traits may be eQTL signals across two or more tissues [Dimas et al., 2009; Fairfax et al., 2012],
eQTL and disease signals [Nica et al., 2010; Wallace et al., 2012] or two or more diseases [Cotsapas
et al., 2011]. Distinguishing cases where related diseases share a common causal variant versus
those where neighbouring but distinct variants appear to underlie disease risk in a region will aid
identification of cross-disease and disease-specific mechanisms. In addition, comparison of disease
and eQTL data has the potential to reveal both the likely disease causal gene in regions where a
number of candidate causal genes exist, and the relevant tissue type where tissue-specific eQTLs
exist. However, dependence between genotypes at neighbouring SNPs, caused by LD, means that
determination of colocalisation is not obvious, as there may exist distinct but neighbouring causal
variants for each trait which are mutually associated.
When these traits are measured in the same individuals, it is possible to use conditioning to
determine whether one trait mediates the other [Li et al., 2011]. For example, if both body mass
index (BMI) and type 2 diabetes (T2D) have been linked to a SNP, then when including BMI and
the SNP as explanatory variables for T2D, BMI but not the SNP should show association if BMI
is a mediator. However, when the traits are measured in distinct samples, or when two traits may
share a common causal variant without one mediating the other, most researchers have approached
the task of looking for colocalisation either by examining by eye the association signals across a set
of common SNPs in the two data sets [Dubois et al., 2010] or by testing for evidence of residual
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association in their available dataset conditional on the most associated SNP in the other [Nica
et al., 2010]. When full data for both traits are available, colocalisation may be tested by examining
whether coefficients from regressions of each trait against two or more SNPs are proportional, as
they should be if those SNPs jointly tag a common causal variant [Wallace et al., 2012; Plagnol
et al., 2009].
We show here that na¨ıve application of both conditional and proportional colocalisation tests
may result in substantially inflated type 1 errors, and explore reasons for that inflation. The inflation
cannot be easily resolved for conditional tests, but we demonstrate two alternative approaches
for proportional testing which result in unbiased inference. Finally, we apply these methods to
colocalisation testing of 13 regions shown in Supplementary Table I which have been associated
with one or both of the autoimmune thyroid diseases, Graves’ disease (GD) and Hashimoto’s
thyroiditis (HT), using previously published dense genotyping data [Cooper et al., 2012].
Methods
Approaches to colocalisation testing
We begin by introducing some notation and setting out the details of the existing approaches to
colocalisation testing that are explored in this paper. Assume two traits, Y and Y ′, have been
measured in distinct samples and evidence exists for association of both traits to some genetic
region. Let the region be covered by p SNPs genotyped in both samples, with the genotype matrices
denoted by X = (X1, . . . , Xp) and X
′ =
(
X ′1, . . . , X ′p
)
respectively. Conditional approaches begin
with identifying the most strongly associated SNPs for Y and Y ′, SNPs k and k′, say, then examine
whether there is any evidence for association between Y and SNP k conditional on SNP k′. The
null hypothesis is therefore
Hcond0 : Y ⊥ Xk|Xk′ . (1)
Concerned that LD would make interpretation of the conditional test difficult, Nica et al.
[2010] extended the conditional method as follows. For every SNP j generate residuals Rj from a
regression of Y against Xj and test the correlation of Rj and Xk using Spearman’s rank correlation
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test, generating p values Pj . The evidence against the null hypothesis (1) is then measured by the
rank of Pk′ in the empirical distribution, [Pj ], generated. This effectively compares the p value
at the test SNP k conditional on SNP k′ to that conditioning on all other SNPs in the region.
However, note that because this method summarizes evidence for colocalisation by a rank only,
there is no statistical inference attached. Thresholds for interpreting ranks would be expected to
depend on SNP density and LD patterns.
The proportional approach frames the null hypothesis differently. A set of q SNPs are chosen
which are deemed somehow to jointly be good predictors of one or both traits. Regressing Y and
Y ′ against these columns of X and X ′ respectively produces estimates, b1 and b2, of regression
coefficients β1 and β2, with variance-covariance matrices V1 and V2 respectively. Since sample
sizes are large, the combined likelihood may be closely approximated by a Gaussian likelihood for
(b1,b2), assuming V1,V2 are known and that Cov(b1,b2) = 0. Assuming equal LD in the two
cohorts, i.e. that the correlation structure between the SNPs does not differ, Plagnol et al. [2009]
show that the regression coefficients should be proportional and proposed testing for a shared causal
variant by testing the null hypothesis
Hprop0 : β1 ∝ β2,
i.e. β1 =
1
ηβ2 = β. The chi-squared statistic
T (η)2 = uTV−1u ∼ χ2 (2)
is derived from Fieller’s theorem [Fieller, 1954], where u =
(
b1 − 1ηb2
)
and V = V1 +
1
η2
V2. If
η were known, T (η)2 would have a χ2 distribution on q degrees of freedom. Plagnol et. al take
a profile likelihood approach and replace η by its maximum likelihood estimate, ηˆ, which also
minimises T (η)2. Asymptotic likelihood theory suggests that T (ηˆ)2 has a χ2 distribution on q − 1
degrees of freedom. Alternatively, Wallace et al. [2012] take a Bayesian approach. They begin by
reparametrising the likelihood in terms of θ = tan−1(η) and rewriting the null hypothesis as
Hprop0 : β1 = β cos(θ); β2 = β sin(θ).
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This allows calculation of the posterior distribution of θ, P(θ|b1,b2), assuming uninformative priors
for θ and β. Inference is based on posterior predictive p values
∫
T ∗(θ)P(θ|b1,b2) dθ (3)
where T ∗(θ) is the p value associated with T (tan(θ)). Full mathematical details are given in the
supplementary material of Wallace et al. [2012], but it is worth revisiting here the justification of
a flat prior for θ. If β1, β2 were univariate with Gaussian priors and mean 0, then tan(θ) =
β1
β2
would have a Cauchy(0, k) prior where k is the ratio of the prior variances of β1 and β2. Thus it
seems an appropriate form to consider for the prior for θ in the multivariate case. k is unknown,
but Wallace et al. [2012] found that varying k had a negligible effect on the posterior predictive p
value for the sample sizes common in GWAS and eQTL studies (100s to 1000s of subjects) and we
have set k = 1, implying a uniform prior for θ, for all analyses in this paper.
Posterior predictive p values have a somewhat different interpretation than and appear conser-
vative in comparison to standard p values [Rubin, 1984; Meng, Sep., 1994]. However, they avoid
assuming the log-likelihood for η is approximately quadratic near its maximum which is not always
the case. In practice, Wallace et al. [2012] found standard and posterior predictive p values to be
almost identical in large samples.
Hprop0 is not the same as H
cond
0 as it does not explicitly condition on the most associated SNPs,
but is a general property expected to be true of any pair of traits which share a common causal
variant. While a shared causal variant should imply Hprop0 is true at any pair of SNPs, and that
Hcond0 is true if k = k
′ is the causal variant, the reverse is not the case as it is possible that two traits
have distinct causal variants in complete LD. Thus, failure to reject the null hypothesis indicates
only that the data are consistent with a shared causal variant.
Note that colocalisation testing may be applied equally to case control data (using logistic
regression), expression data (using linear regression) or to compare case control results against
expression results for a specific gene. Most commonly, this last approach might be applied in turn
to all genes with a known eQTL signal in the neighbourhood of the disease association signal.
However, it is assumed that cov(b1,b2) = 1, meaning that case control studies may only be
compared if they do not share a common control group.
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Choice of SNPs for proportional colocalisation testing
The choice of SNPs for colocalisation testing will be shown in this paper to have a considerable
influence on the type 1 error rate of colocalisation tests. For the proportional approach, two
strategies have been applied. Either colocalisation has been tested using the pair of SNPs k and k′
defined above [Plagnol et al., 2009] or a lasso approach, where SNPs are first selected in a lasso for
one trait, and then additional SNPs are selected in a further lasso for the other trait [Wallace et al.,
2012]. However, as shown by Miller [Miller, 1984], any variable selection method must induce bias
in the estimated coefficients (b1, b2) if the estimation occurs in the same dataset as the selection.
The aim of selecting the most informative subsets of SNPs for proportional colocalisation testing
is to minimise the degrees of freedom of the test, and hence maximize power. However, unless
independent data are available for variable selection, this increase in power comes at a cost to
type 1 error rate control as shown above. In this paper, we propose two methods for avoiding this
problem.
Summary of genetic variation by principal components If the region of interest displays
strong LD, a modest number of principal components (PCs) are generally required to capture most
of the SNP variation (Supplementary Figure 9) and we can use a subset of the most informative
components for colocalisation analysis. Because PCs are by definition uncorrelated, and because the
selection is not based on their relationship to the traits of interest, the estimated coefficients at any
such subset are unbiased. To allow PC analysis of two datasets, we first form a combined genotype
matrix, center and scale each SNP, and then define the principal components. Colocalisation testing
is performed using the projection of the data onto the transformed basis for the most important
components. The optimal choice of threshold defining the “most important” components is not
obvious, and we explore that in our simulations.
Bayesian Model Averaging Alternatively, we may combine the ideas of Bayesian model aver-
aging (BMA) [Viallefont et al., 2001] and posterior predictive p values, to treat the model describing
the joint association itself as a nuisance parameter, and average the p values not just over the pos-
terior for η, but also over the posterior for all SNP selection models. Analogous to equation (3),
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posterior predictive p values are therefore defined by
ppp =
∑
m∈M
p∗(m)P(m) (4)
where M is the set of models under consideration, p∗(m) is the colocalisation testing p or ppp
value under the SNP model m, P(m) is the posterior probability of model m given the data and
under the assumption that one ofM is the true model. To minimize the degrees of freedom of the
test, we explore all two SNP models and, in the absence of any independent evidence to favour one
SNP over another, we assume the prior is evenly spread over the set of models. Approximating the
posterior probabilities by means of the Bayesian Information Criterion approximation [Schwarz,
1978; Hoeting et al., 1999] and discarding highly improbable models at the outset, this could be
done without excessive computational burden (see Supplementary Material for full details).
Both the PC and BMA approaches are available in our R [R Development Core Team, 2010]
package, coloc, available from the Comprehensive R Archive Network (http://cran.r-project.
org/web/packages/coloc).
Simulation
We used simulation to demonstrate the effects of variable selection on the power and type 1 error
rate for colocalisation testing. Full details are given in supplementary material. Briefly, we sampled,
with replacement, haplotypes of SNPs with a minor allele frequency of at least 5% found in phased
1000 Genomes Project data [Consortium et al., 2012] across all 49 genomic regions outside the
major histocompatibility complex (MHC) which have been identified as type 1 diabetes (T1D)
susceptibility loci to date, as summarized in T1DBase [Burren et al., 2011]. These represent a
range of region sizes and genomic topography typical of GWAS hits. We excluded the MHC
region which is known to have high variation, strong LD and exhibits huge genetic influence on
autoimmune disease risk involving multiple loci and hence requires individual treatment in any
GWAS [Nejentsev et al., 2007].
Using a single “causal variant” SNP chosen at random, we sampled case and control haplotypes
according a multiplicative disease susceptibility model with relative risks of ranging from 1.1 to 1.3
to represent GWAS data. To simulate a quantitative trait, and to extend our exploration to two
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causal variants in each trait, we selected one or two “causal variants” at random, and simulated
a Gaussian distributed quantitative trait for which each causal variant SNP explains a specified
proportion of the variance. To reflect our expectation that this test will be applied in cases in
which some nominal association to a region has already been established, we discarded datasets in
which all single SNP association p > 10−4. We either used all SNPs or the subset of SNPs which
appear on the Illumina HumanOmniExpress genotyping array to conduct colocalisation testing to
reflect the scenarios of very dense targeted genotyping versus a less dense GWAS chip. All analyses
were conducted in R [R Development Core Team, 2010] using the coloc package for proportional
colocalisation testing.
Colocalisation testing for autoimmune thyroid disease
An association study of the autoimmune thyroid diseases GD and HT has recently been completed
using the Immunochip for genotyping, which provides dense coverage of regions of the genome
previously associated with autoimmune disease [Cooper et al., 2012]. The paper presented a total
of 2285 Graves’ disease cases, 462 Hashimoto’s disease cases and 9364 controls. We split the controls
randomly into two groups of size 4682, and analysed each of the 13 regions reported to be associated
with one or both diseases [Cooper et al., 2012]. Missing data were rare, but regression models
require complete genotyping data. We therefore imputed missing genotypes by means of multiple
regression, as implemented in the R package snpStats [Clayton and Leung, 2007]. We conducted
proportional colocalisation analysis using the the two alternative methods set out above. For the
PCs approach, we used components that captured at least 90% of the observed genetic variation.
For the BMA approach, we averaged either over the universe of all possible two SNP models or
that of all three SNP models.
Results
Naive application of colocalisation tests leads to biased inference
The choice of SNPs to use for testing can induce bias for two reasons. First, selecting the “most
associated” SNP on the basis that the evidence for its association is strongest amongst all SNPs
tested does not guarantee either that it is the causal SNP or even the best proxy. Random variation
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and LD mean that evidence for association may peak at an alternative SNP even when the causal
SNP is included in the genotyping panel, a bias which is more pronounced for weaker effects and
smaller sample sizes (Supplementary Figure 6). Second, although it is well known that regression
coefficients are unbiased estimates of population effects, this property does not hold after variable
selection [Miller, 1984], an effect which has been referred to as “Winner’s curse” in genetics [Gring
et al., 2001; Lohmueller et al., 2003]. Choosing SNPs on the basis of their significance or some other
measure of strength of association induces a bias away from the null - i.e. coefficients of selected
SNPs are expected to overestimate the true effect - and again the effect is more pronounced for
smaller sample sizes and weaker effects (Supplementary Figure 7). These two biases mean that, in
conditional testing, there is likely to be some residual association between the phenotype Y and the
remaining genetic markers after conditioning on the selected SNP k′ because (1) the conditioning
SNP k′ may not capture all the true association and (2) the estimated effect at the tested SNP k
tends to be an overestimate. The result is very poor control of the type 1 error rate (Figure 1, track
C1). Conditioning on the common causal variant rather than the most associated SNP (which is
only possible in simulation studies) reduces the bias by removing the SNP selection problem, but
does not eliminate it due to the overestimation of effect size (Figure 1, track C2).
As seen in Supplementary Figure 8, Nica’s score tends towards to 1 for traits that share a causal
variant and is uniformly distributed on [0, 1] for distinct unlinked causal variants. Its distribution
is increasingly skewed towards 1 as the LD between distinct causal variants increases. This makes
sense if one considers that the case of two distinct variants in some LD lies partway between
the extreme cases of distinct linked causal variants and a single common causal variant, which is
equivalent to distinct causal variants in complete LD. The effect of using the most associated SNPs
for testing compared with using the true causal SNPs is to reduce the skew towards higher rank
scores as the r2 between variants increases. Thus, Nica et. al ’s extension [Nica et al., 2010] is useful
if searching for most likely colocalisation signals within a set, but as it avoids formally testing a null
hypothesis, and because the scale against which to interpret the rank score is likely varies according
to effect size, it does not provide a means to assess evidence for or against colocalisation at a given
locus of interest.
We show here that neither published method of SNP selection in proportional testing maintains
control of the type 1 error rate (Figure 1, tracks P1, P2 and P3), although the bias is less extreme
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than for conditional testing. The two-step lasso selection defined above does reduce bias compared
to independent lasso selection in the two datasets, but, perhaps counter-intuitively, leads to greater
bias than simply testing the pair of most associated SNPs (k, k′) when only tagging genotypes are
available and effect sizes are large (relative risk ∼ 1.3). This is because, in this situation, lasso
may select SNPs which are apparently weakly associated (either truly or through random noise) at
which, as demonstrated in Supplementary Figure 7, effect estimates are more strongly biased.
Proper control of type 1 error rates
Principal components When using principal components to summarize the genetic variation in
a region, it is not obvious how many components are required. As more components are selected,
more information about the genetic variation in a region is captured, and hence we are more
likely to accurately capture the signal of any causal variants. However, successive components add
decreasing amounts of information whilst still adding another degree of freedom. At some point
the negative effect of increasing degrees of freedom will outweigh the positive effect of increasing
information, and we were concerned that the optimal test may depend heavily on the threshold
used to determine the number of components selected. Instead, power seemed broadly acceptable
once components capturing 70-90% of variation were selected (Supplementary Figure 10). In our
49 test regions, 70% of the variance could be captured by selecting an average of 7 (range 2-18) or
9 (range 3-44) components under a tagging or complete genotyping approach.
We found type 1 error rates were controlled across the range of thresholds explored, but show
for illustrative purposes the results when we fixed the threshold at ≥90% of genetic variation
(Figure 1). We examined power to detect departure from colocalisation using simulations in which
the causal variants are distinct for two traits but placed no restrictions on the LD between these
variants. We first examine the theoretical maximum power of the test by testing the two causal
variants themselves, which are known in a simulation study but not in real data (Figure 2). As
might be expected, power increases with sample size and effect size, but is negatively correlated
with the r2 between the causal variants, and is maximum when the two are completely unlinked
(r2 = 0). When using PCs, the power is reduced reflecting the loss of information in not knowing
these causal variants, but the loss is greatest for complete genotyping scenarios, suggesting that we
may be selecting too many components in the case of complete genotyping and emphasizing the
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difficulty in choosing one optimal threshold for all studies and regions.
Bayesian Model averaging Because of its computational burden for simulations, we only con-
sider the BMA approach under a tagging genotyping scenario. This demonstrates good control of
the type 1 error, even tending to be mildly conservative, as has previously been reported when pos-
terior predictive p values are interpreted similarly to standard p values [Meng, Sep., 1994]. Despite
the slightly more conservative type 1 error rates, the BMA approach appears more powerful than
the PCs approach (Figure 2), which presumably reflects the greater degrees of freedom required for
the PCs approach.
Sensitivity to the assumption of equal linkage disequilibrium
The proportional colocalisation test assumes identical patterns of LD in the two datasets so that
the effect of a shared causal variant is proportional across any set of SNPs. To explore its sensitivity
to this assumption, we considered sampling haplotypes for one dataset from a subset of European
populations, and for the other dataset from a either a mixture of European populations or a mixture
of European and African populations. As might be expected, for strongly admixed datasets, the
control of type 1 error rate is lost, with type 1 error rates up to 8 fold that seen under the case of no
mixing (Figure 3). However, it is perhaps surprising that the effect of mixing between two European
populations, or mixing very small proportion of African haplotypes (∼ 5%) into a mainly European
population, is barely detectable at the sample sizes of 1,000 used, and indicates that the method
is not very sensitive to small departures from the assumption of equal linkage disequilibrium. Of
course, as with any genetic analysis, it remains sensible not to rely on this property, but to formally
examine the evidence for population structure and exclude obviously outlying samples.
The case of multiple causal variants
So far, we have only considered the case of a single causal variant for each trait. But the pro-
portional test makes no assumption about the number of causal variants, only that their effects
are proportional. Figure 4 shows that in the case of eQTL data with two shared causal variants,
having equal effects on each trait, type 1 error rates are still controlled. It has been reported that
genes may exhibit a common cross-tissue eQTL, located proximal to the gene, as well as distinct
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tissue specific eQTLs in more distal locations [Brown et al., 2012]. We were therefore interested
to explore the case where our two traits share one causal variant, but one or both are also under
the influence of additional, distinct variants. Testing a single hypothesis of colocalising versus not
colocalising variants cannot capture the complexity of this situation, but it is instructive to ex-
plore the test’s expected behaviour in order to allow proper interpretation with real data where
the number, and sharing configuration of causal variants is unknown. Figure 4 shows that, under
a tagging genotyping scenario, the proportional test tends to reject the null of colocalisation in the
case of any distinct causal variants, even in the presence of an additional shared variant, although
with slightly less power than when there is no shared variant.
Varying the number of SNPs in Bayesian Model Averaging models
So far, also, we have assumed that it was enough to consider only the universe of two SNP models
when applying our BMA approach. The motivation for this was that a two SNP model leads to
a one degree of freedom test, and might therefore be expected to maximise power. We examined
the effect of averaging over either all two SNP or all three SNP models in the context of the above
multiple causal variant simulations. This shows that type one error rates are similar, that power is
similar for two SNP models, but that power can be increased by averaging over three SNP models
compared to two SNP models, particularly when there are really three or more distinct causal
variants (Figure 4)
Application to colocalisation testing of Autoimmune Thyroid Diseases
Existing evidence suggests that a single locus may contain variants which predispose to any one of
multiple diseases, e.g. the non-synonymous C1858T SNP in PTPN22 is associated with rheumatoid
arthritis and T1D [Stahl et al., 2010; Barrett et al., 2009], or distinct variants which predispose to
different diseases, e.g. distinct variants in IL2RA are associated with T1D and multiple sclerosis
[Maier et al., 2009; Martin et al., 2012]. We used the proportional colocalisation approach outlined
above to examine the disease signals for the autoimmune thyroid diseases HT and GD from a recent
dense genotyping study [Cooper et al., 2012].
We first examined the seven regions where a significant single SNP effect has been identified in
both diseases, i.e. at study-wide significant levels for GD (p < 1.1 × 10−6, a permutation derived
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threshold specific to this study) and at a nominal significance threshold of p < 0.05 for HT. Six of
these display no evidence against colocalisation (all posterior predictive p > 0.01), the exception
being 2q33.2/CTLA4/ICOS in which the ppp value for the BMA approaches is 6 × 10−3 (two
SNP models) or 8 × 10−5 (three SNP models). In this region, the profile of the single SNP p
values do differ (Supplementary Figure 11), but it would require larger sample sizes to confidently
conclude that the two diseases have different causal variants in this region given the number of
tests completed.
The coefficient of proportionality, η, can be usefully interpreted when analysing two diseases.
Two values of particular interest are η = 0 which would indicate no effect in HT given an effect
in GD and η = 1 which indicates equal effects in each disease. In most of the seven regions, the
credible interval for η includes 1 (Figure 5), the exceptions being 2q33.2 and 10p15.1, where it ends
just below 1 using a PCs approach, and 3q27.3/3q28/LPP where it starts just above 1 on either
BMA approach.
Turning to the the six regions where there is evidence of association in only GD, we do not expect
to see any departure from the null of colocalisation, without evidence of association to both traits,
and indeed all posterior predictive p > 0.01. However, our estimate of η helps infer whether this
reflects a lack of power or genuine absence of association for HT. We evaluated the credible intervals
for η in each region and across four of the six regions, the credible interval for η includes 0, whilst in
only one does the credible interval include 1 for all approaches. In one 14q31.1/TSHR, the credible
interval ends just below 0 for the BMA approaches, whilst for 6q27/CCR6, it starts just above 0
and includes 1 for all methods. TSHR represents the primary autoantigen in hyperthyroidism of
GD [Brand and Gough, 2010], so is unlikely to be involved in HT.
Discussion
There are two sources to the bias in colocalisation testing presented above. The problem of variable
selection is well studied in statistics generally [Miller, 1984] but has perhaps been neglected in
statistical genetics, where the aim has been to detect convincing association to a region, rather
than pinpoint the causal variant, particularly as most datasets to date have included an incomplete
selection of variants in any region. Selecting SNPs which do not fully capture the trait association
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will affect conditional colocalisation testing because some residual association must remain after
conditioning. On the other hand, it should not bias proportional testing as the aim there is to
test for proportionality of effect size rather than evidence of residual effect. This may explain the
substantially higher error rates for naive conditional testing versus naive proportional testing seen
in Figure 1.
The bias in effect size estimates affects both methods, however. In genetics, we are familiar with
“Winner’s curse”, which causes effect estimates which are examined conditional on the associated
p value being below some significance threshold to be biased away from the null. Some attempts
to correct this effect size bias have been made, either by modelling a selection procedure defined
as a single SNP exceeding a predetermined level of significance [Zollner and Pritchard, 2007], or
by bootstrapping which can in theory account for the full selection strategy [Sun et al., 2011]. We
explored both approaches, but found neither led to unbiased or even nearly unbiased inference (data
not shown). For Zollner and Pritchard [2007], this failure is presumably down to the discrepancy
between correcting for a p value that exceeds some threshold and selecting SNPs with the minimum
p values. In the case of Sun et al. [2011], it is possible that single loci do not contain sufficient
information for a bootstrap based correction; the corrected estimates tended to be biased in the
opposite direction, suggesting the method was over-correcting.
Our proposed solution is to use proportional testing and either avoid variable selection altogether
by using the PCs which capture the majority of genetic variation in the region under test, or
integrate over the variable selection using BMA. Either method maintains type 1 error, and the
BMA approach appears more powerful than the PC approach, although both have reduced power
compared to the hypothetical scenario of being able to test the causal variants themselves. Recall
from equation (4) that the ppp depends on both the posterior probabilities of individual SNP models
and the degree of departure from the null under each model, p∗(m). If the posterior probability was
spread broadly over the model space and p∗(m) varied considerably across models, the distribution
of ppp would be far from uniform, with too few observations in the tails. The fact that we observe
only mildly conservative type 1 errors, even in the weakest associations considered here (case control
sample sizes of 2000, and relative risks of 1.1), probably reflects our requirement in simulating our
datasets that some nominal level of association must be observed for at least one SNP in a region.
This means that, for our simulated data, the posterior probabilities tend to be mainly focused on a
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small subset of models, and these models tend to contain sets of SNPs related by LD so that p∗(m)
does not vary substantially across the set of models on which most of the posterior probability is
concentrated. Whether caution is needed in applying this approach in smaller datasets depends
somewhat on a researcher’s view. Certainly, it is unlikely that the ppp distribution would be uniform
if small samples with weak associations were used, and therefore power to detect departure from
colocalisation would be reduced. However, the alternative to colocalisation being tested is not just
that of no colocalisation, but implicitly that of distinct causal variants in two traits. If there is
weak or only limited evidence for association with either trait, then it does seem appropriate that
one cannot reject a null of colocalising causal variants in favour of an alternative distinct causal
variants. On the other hand, if evidence for association has been independently established, a
researcher may be sure that there are causal variants for each trait although there is only weak
evidence in the currently available datasets, in which case they may wish to explore calibrating the
ppp distribution, for example by means of simulation [Hjort et al., 2006], so that its null distribution
is uniform between [0, 1].
Regions are typically defined after GWAS studies according to genetic distance in order to
describe the physical region within which a causal variant tagged by the association is expected to
lie. T1DBase uses a definition of 0.1cM surrounding any single SNP with p × 10−8 and we used
a 0.1cM window around the most associated SNP in our AITD analysis. If regions were defined
more broadly, one might expect the BMA method to be relatively unaffected, as SNPs beyond
the boundary of the current regions would not show much evidence for association. On the other
hand, we expect the power of the PC approach would decrease, as the number of components, and
therefore the degrees of freedom of the test, would increase without any compensatory increase in
information.
We have proposed alternative approaches to colocalisation testing, but how should a researcher
choose which approach and the parameters specific to that approach? Our view is that we would
use PCs as a first pass if many loci are under consideration, to prioritise regions for more detailed
analysis. The optimal number of components is unknown, but a number that captures something
in the region of 70–90% of genetic variation seems acceptable. However, if evidence for association
is strong in both datasets, BMA is a more powerful approach and there seems little reason beyond
computational expense to prefer averaging over the universe of two SNP models to that of three
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SNP models. However, in large regions, a relatively modest number of SNPs can cause the number
of three SNP models to be infeasible. For example, 100 SNPs can generate 4,950 two SNP models
but 161,700 three SNP models. We would not suggest exploring four SNP models because that
seems likely to spread the posterior probabilities very thinly, and we haven’t explored combining
two and three SNP models because it is unclear what prior weight should be given to a two SNP
compared to a three SNP model.
As an example application of our proposed approaches, we analysed 13 loci associated with the
autoimmune thyroid diseases GD and HT. Reassuringly, inference was broadly similar regardless of
method, and we and showed that in the seven regions where a locus has been associated with the
two diseases, the data are generally consistent with common causal variants exerting an equal effect
on each disease. In regions previously significantly associated with only GD, posterior predictive p
values are unlikely to detect any departure from colocalisation for reasons described above, but here
the Bayesian approach does allow us to use make some inference using the posterior distribution
of η. Given the relatively smaller number of HT cases (462) compared to GD (2285), it might be
expected that many of the loci only associated with GD have failed to be reach significance for
HT due to lack of power. Estimates of power to detect association with HT under the assumption
of equal effects in GD and HT are broadly similar across the seven regions associated with both
diseases and the six regions associated with GD only (Supplementary Table I), but these are likely
to be over optimistic due to the expected bias in the GD effect size estimates. However, for five of
these six regions, the evidence suggests that failure to detect association with HT is more likely to
be due to a discrepancy in effect size, with the effect considerably larger in, and possibly specific
to GD, compared to HT, rather than a lack of power. However, while the data suggest that LPP
may have a stronger effect on GD compared to HT, and that CCR6 may be an undetected HT
locus, the small sample size for HT prevents us from drawing this conclusion with any confidence.
There is a pressing need for more widespread use of formal colocalisation testing. Researchers
are turning to eQTL data to interpret GWAS results by simply considering whether an eQTL SNP
is associated with any disease [Nicolae et al., 2010], visually [Trynka et al., 2011], by conditional
testing [Nica et al., 2010], by naive application of a proportional colocalisation test [Plagnol et al.,
2009; Wallace et al., 2012] or by attempting to integrate disease and gene expression association
signals in networks [Hao et al., 2012]. Where colocalisation tests have been naively applied, we
17
expect the null hypothesis of colocalisation has been rejected too readily, although this will affect
loci with small and moderate effects to a greater degree than those with large effects. Thus, for
our earlier analysis of colocalisation between T1D and monocyte gene expression signals [Wallace
et al., 2012], the list of loci compatible with colocalisation are likely correct, but some loci were
probably erroneously rejected, and re-analysis of these data will be required.
In the case of network analysis, results can be difficult to reconcile with simple representations
of the data. For example, integration of lung expression and asthma genetic association data led
to the identification of GSDMA as the most likely causal gene for asthma in the 17q21 region [Hao
et al., 2012], despite a graphical representation of the data showing that the SNPs most strongly
associated with GSDMA expression were relatively weakly associated with asthma, and, vice versa,
that the SNPs most strongly associated with asthma showed relatively weaker levels of association
with GSDMA expression compared to the strongest signals. The asthma association on the 17q21
region was one of the first cases of explicitly using expression data to interpret disease association,
with the association with asthma initially attributed to ORMDL3 based on expression data from
EBV transformed cell lines [Moffatt et al., 2007] and subsequently to GSDMB from a reanalysis
of the same data [Moffatt et al., 2010]. Candidate gene hypotheses have been constructed for all
three genes. The lung expression data have greater potential for revealing the underlying gene, but,
to hold confidence in results of analyses, particularly when the results contrast with simple visual
inspection of the data, requires careful examination of the properties of the statistical method used.
Given the tissue-specific nature of many eQTLs identified to date [Dimas et al., 2009; Fairfax
et al., 2012], there is a need for more large, publicly available eQTL datasets in a variety of
disease relevant tissues and purified cell subsets to support the interpretation of existing GWAS
data. Although expression data is typically shared after the publication of an eQTL study, we
note that the genetic data must also be made available to allow full integration of eQTL and
disease signals at shared loci. The increasing abundance of substantial GWAS datasets and the
increasing availability of large eQTL datasets [Fairfax et al., 2012; Fu et al., 2012; Hao et al.,
2012], together with our reassurance that it is possible to conduct these tests whilst maintaining
type 1 error rates and the availability of software in our R package will facilitate more widespread
formal colocalisation testing. Integration of genetic association data has the potential to refine
understanding of underlying genetic mechanisms and aid in the design of follow-up studies already
18
underway.
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Figure 1: Type 1 error rates in naive colocalisation testing. A nominal type 1 error rate of 5%, shown
by a dashed line, is consistently exceeded using conditional colocalisation testing conditioning on
either the most associated SNP for the other trait (C1) or the common causal SNP which is only
possible in simulated complete genotyping data (C2). Proportional colocalisation testing tends
to exhibit lower type 1 error rates, but the excess can still be substantial when using the most
strongly associated SNPs in each dataset (P1); the union of lasso variable selection in each dataset
(P2) or a two stage lasso variable selection (P3) as previously described [Wallace et al., 2012]. In
contrast , type 1 error rates are well controlled for proportional testing using principle components
which capture 85% of the genetic variation (P4) or within a Bayesian Model Averaging approach
to variable selection (P5), even appearing conservative for small effect sizes. Note that Bayesian
Model Averaging was not examined in the complete genotyping scenario due to computational
burden. The X axis shows the relative risk of disease (RR) with columns divided according to
the number of cases and controls in a case-control dataset. Type 1 error rates were calculated by
comparing two case-control datasets of equal sample and effect size, simulated to share a common
causal variant.
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Figure 2: Power for proportional colocalisation analysis using PC or BMA approaches. The the-
oretical maximum power (Max) is calculated by proportional colocalisation testing using the two
causal variants which are known in simulated data and show that the predominant determinant
of power is the r2 between the variants, with power decreasing as LD increases. When the causal
variants are not known, power decreases under either a PC or BMA approach. The X axis shows
the maximum r2 between the causal variants, i.e. r2 has been categorised into 5 groups: [0, 0.2],
(0.2, 0.4], (0.4, 0.6], (0.6, 0.8], (0.8, 1.0]. N is the number of cases and controls in a case-control
dataset with relative risk of disease RR. Power is shown for comparing two case-control studies
with equal sample numbers and effect sizes (solid lines) or for comparing a case-control study to
an eQTL study of 1000 samples where the causal variant explains 30% of the variance of the ex-
pression. The PC approach was implemented by selecting the smallest subset of components which
captured 85% of the genetic variance. We considered only tagging genotype scenarios to reduce
computation time.
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Figure 3: Departure from assumption of equal LD structure. Each plot reflects simulations in which
a single, common causal variant explains a fixed proportion of variance of two quantitative traits,
shown on the x axis, each available in a sample of 1,000 individuals. In the top row, all haplotypes
in the first dataset and (1 − pi) of the haplotypes in the second dataset were sampled from the
European CEU, GBR and FIN populations, and the remaining pi in the second dataset from the
alternate European TSI and IBS populations. In the bottom row, we used the same strategy but
sampling either from all European populations (CEU, GBR, FIN, TSI and IBS) or from a mixture
of these European populations and the African ASW , LWK and YRI populations. The y axis
shows the relative type 1 error rate - the ratio of the estimated rate for the given scenario and the
estimated rate for the equivalent scenario with no mixing. Because these are ratios, there is rather
less certainty than for other plots and 95% confidence intervals calculated by means of the delta
method are shown for each point. Analysis was conducted by proportional testing using either a
PC approach with number of principal components selected to capture 90% of genetic variation or a
BMA approach, averaging over the space of either all possible two SNP models. We considered only
tagging genotype scenarios. CEU=Utah Residents (CEPH) with Northern and Western European
ancestry; GBR=British in England and Scotland; FIN=Finnish in Finland; TSI=Toscani in Italia;
IBS=Iberian population in Spain; ASW=Americans of African Ancestry in SW USA; LWK=Luhya
in Webuye, Kenya; YRI=Yoruba in Ibadan, Nigera
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Figure 4: Effect of more than two causal variants. Each plot reflects simulations in which causal
variants in total explain a fixed proportion of variance of two quantitative traits, shown on the x
axis, each available in a sample of 1,000 individuals. The total number of causal variants is shown
by the number of circles above each plot, with full circles indicating a causal variant shared by
both traits and half shaded a causal variant associated with one trait or the other. Analysis was
conducted by proportional testing using either a PC approach with number of principal components
selected to capture 90% of genetic variation or a BMA approach, averaging over the space of either
all possible two SNP or three SNP models. We considered only tagging genotype scenarios.
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Figure 5: Colocalisation analysis of Graves’ and Hashimoto’s diseases. Regions are labelled by chro-
mosome and likely candidate gene(s) and arranged so that the top seven regions showed marginally
significant association with both GD and HT (p < 0.05) and the bottom six with just GD in the
published single SNP analysis [Cooper et al., 2012]. The left panel shows the estimate of the co-
efficient of proportionality, η, for the estimate of the ratio of effect sizes in HT compared to GD,
and its 95% credible interval, calculated using either the PCs approach (PC), or BMA averaging
over two SNP models (BMA.2) or three SNP models (BMA.3). The middle panel shows the the
evidence against colocalisation using either the − log10(p) value (PCs) or the posterior predictive
− log10(p) (BMA). The right panel summarizes the evidence for association of the region with each
disease using − log10(p) values for the association analysis of Graves’ and Hashimoto’s using the
selected principal components for the PCs approach. The − log10 scale has been truncated at 10
so that more extreme p values are displayed at − log10(p) = 10. For the PC approach, testing was
based on the smallest subset of components that captured 90% of the genetic variance.
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Supplementary Material
Simulation
Once a “causal variant” SNP, S, was selected, control haplotypes were sampled randomly and case
haplotypes sampled conditional on the allele carried at S. For a disease model with relative risk r,
and given the minor (risk) allele at S has frequency pi0, in controls, the frequency in cases is
pi1 =
rpi0
1− pi0 + rpi0 .
Therefore when sampling case haplotypes, we over-sample haplotypes carrying the risk allele and
under sample those carrying the protective allele by using sampling probabilities proportional to
PS =

pi1
pi0
haplotype carries risk allele
1− pi1
1− pi0 haplotype carries protective allele allele.
For eQTL data, we simulated a response variable, Y as a mixture of Gaussians
Y =
√
0.7Z +
√
0.3X
where Z was sampled from a standard Gaussian and X is the count of the minor allele at the causal
SNP. Thus, X would explain 30% of the variance of Y , or 30% of the simulated eQTL, independent
of minor allele frequency.
The effect size at a selected SNP
To calculate the bias in figure 7, we compared the estimated effect size at the sampled SNP to the
true effect at that SNP, ie not at the causal SNP. If the causal SNP is S and the selected SNP
is T , then the underlying relative risk at T is simplest to calculate in a haploid system, which is
equivalent to assuming Hardy Weinberg equilibrium. Given
ρ′ = ρ(S, T )
√
piSpiT (1− piS)(1− piT )
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where ρ(S, T ) is the correlation between S and T , then the expected proportion of cases in the
population conditional on the allele carried at SNP T is

D1 =
r(piSpiT + ρ
′) + ((1− piS)piT − ρ′)
piT
T is risk allele
D0 =
r(piS(1− piT )− ρ′) + ((1− piS)(1− piT ) + ρ′)
1− piT T is protective allele
and the relative risk is
D1
D0
. For a rare disease such as T1D, relative risks and odds ratios are
approximately equal.
Implementation of Bayesian Model Averaging
Bayesian model averaging requires evaluating all possible multiple SNP models in each trait, and
conducting colocalisation testing for each model. We began by defining the posterior probability
of model j for both traits as,
pij =
pi1jpi
2
j∑
k pi
1
kpi
2
k
where piij is the posterior probability of model j for trait i and a model j indicates which SNPs are
included in the model. Even when the number of SNPs to be tested is fixed at two, the number
of possible models is p!2!(p−2)! . Whilst testing all models is feasible if computationally expensive
for analysis of real data, it is impractical for simulations. To reduce the computation burden, we
first evaluated all p single SNP models and indentified the set of SNPs with very low posterior
probability (pij < 0.01). We then excluded any two SNP model containing only SNPs from this set.
If p0 < p such SNPs were identified, this reduced the number of models to test to
p!
2!(p−2)! − p0!2!(p−2)! .
For the purposes of simulation, we used the profile likelihood approach to generate a χ21 dis-
tributed test statistic and averaged the resulting p values, Pj , over the model space to calculate
an overall posterior predictive p value,
∑
j Pjpij . For the application to AITD, we integrated the p
value associated with the χ22 distributed test statistic calculated assuming η was known over both
the posterior distribution of η given each model, and the posterior of the model space. The latter
is formally correct, but comptationally too expensive for simulation, and the profile likelihood p
value and the posterior predictive p value have been shown to be very similar for large samples.
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Supplementary Figure 6: The most associated SNP in a region is not necessarily the
causal SNP. Boxplots show the distribution of r2 between the SNP with the smallest p value
(conditional on p < 1 × 10−8) and the causal SNP from simulated data, either under tagging
or complete genotype coverage. Increasing the effect size increases the range of tagging SNPs
detectable, and hence can have the apparently counter-intuitive result of decreasing the correlation
between selected and causal SNPs. However, if complete genotype coverage is available, the LD
between selected and causal SNPs tends to increase with effect size or sample size.
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Supplementary Figure 7: Effect sizes at selected SNPs tend to be overestimated. Boxplots show
the distribution of the ratio of the estimated effect size (βˆ) to the true effect size (β) at the most
associated SNP in a region. Simulations were conducted for samples of N cases and N controls,
with a relative risk at a randomly selected “causal SNP” of 1.1, 1.2 or 1.3, under either a complete
genotyping scenario (all SNPs in 1000 Genomes, top row) or the subset of SNPs appearing on the
Illumina Human Omni Express chip chip (“Tagging”, bottom row). Estimated effects are more
likely to be biased for smaller effect sizes and sample sizes.
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Supplementary Figure 8: Distribution of Nica et. al ’s rank statistic. The statistic is evenly
distributed within [0,1] when the LD between the causal variants is negligable, but is increasingly
biased towards 1 as the LD increases. Columns are divided by the r2 between distinct causal
variants, with r2 = 1 indicating a shared causal variant. The top row shows the optimal result that
could be obtained if conditioning on the true causal variant were possible, the bottom row shows
the effect of conditioning on the most associated SNP is to reduce the degree of skew. Results are
shown for a complete genotyping scenario, with a sample size of 2000 and a relative risk of 1.3.
Similar effects are seen under tagging or complete genotyping approaches, but the skew towards 1
occurs more rapidly with larger samples and effect sizes.
36
0500
1000
1500
2000
0
50
100
Com
plete
Tagging
0 10 20 30 40 50
Region number
N
um
be
r o
f S
NP
s
Threshold
Total
99
98
97
96
95
90
85
80
70
60
50
Supplementary Figure 9: The number of principal components required to capture a
predefined proportion of the variance. The 49 regions used for simulation are displayed,
unlabelled and ordered by the total number of SNPs. The majority of variation can be captured
by a relatively modest number of components even for regions containing large numbers of SNPs.
Threshold specifies the minimum proportion of variance captured, or “Total” for the total number
of SNPs in a region.
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Supplementary Figure 10: Power using colocalisation testing of principal components ac-
cording to the proportion of genotype variance captured. Power is shown for all simulated
datasets where the r2 between the causal SNPs was less than 0.5.
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Supplementary Figure 11: Single SNP p values for GD and HT in the CTLA4/ICOS region on
2q33.2.
39
